Pfizer signs a cooperation deal with Gilead for remdesivir, a COVID 19 medication

 

Pfizer signed a cooperation deal with Gilead Sciences to produce and supply remdesivir, a promising drug used to treat COVID-19. According to this agreement, Pfizer shall provide production services at its McPherson, Kansas factory in the US. The company would be manufacturing and supplying the drug remdesivir for Gilead.

After signing the cooperation agreement, Pfizer became a promising company in the fight against COVID-19. The deal is aligned with the “innovation ecosystem” that commits to fight a battle against COVID-19 pandemic. The agreement has brought about a fruitful collaboration between small biotech companies and large pharmaceutical companies. Many government agencies associated with academia would be benefitted from this cooperation.

The COVID-19 pandemic has become a real menace, and a single company cannot really bring about an innovation and put an end to the COVID-19 menace. The deal between Pfizer and Gilead would be good enough to bring about an innovative ecosystem, which will deliver effective medical solutions. Both companies would be working together to manufacture vaccines, sterile injections, and biologics.